Αρχική World News FDA Approves Cabozantinib for Adults and Paediatric Patients 12 Years of Age... World News FDA Approves Cabozantinib for Adults and Paediatric Patients 12 Years of Age and Older with pNET and epNET Από Ogkologos - 18 Απριλίου, 2025 910 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the CABINET study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR FDA Approves Pembrolizumab for Advanced MSI-H/dMMR Endometrial Carcinoma 5 Απριλίου, 2022 Announcing ‘Cancer Revolution’ – a world-first exhibition to engage people with... 28 Ιουλίου, 2021 Rare Disease Day 2026: Advancing equity for people living with rare... 27 Φεβρουαρίου, 2026 Breast Cancer Patient Devotes Her Time to Driving Others to Treatment 15 Μαρτίου, 2021 Φόρτωση περισσοτέρων HOT NEWS 49-Year-Old Breast Cancer Patient Grateful She Didn’t Wait Until 50 for... What to Know About Getting Access to New Cancer Advances Presented... ASCO Annual Meeting 2023: Improving Outcomes in Glioma, Hodgkin Lymphoma, Lung... 2021 ASCO Annual Meeting Research Round Up: Advances in Treating Brain...